EUVIMEDEUVIMED entdecken
Vergleichsstudie

A Retrospective Comparison of Survival, Tumour Reduction and Relapse Outcomes Following Oclacitinib and CCNU Treatment in Dogs With Canine Epitheliotropic T‐Cell Lymphoma

Guanshen Brian Shen iD, Manijeh Mohammadi Dehcheshmeh iD, Esmaeil Ebrahimie iD, Evie Knight iD, Darren J Trott iD, Michael Shipstone

Veterinary Dermatology · 2026-12 · 37 (6) · 1012-1019

DOI: 10.1111/vde.70115 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Veterinary Dermatology, online erschienen am 05.08.2026. Verfasst von Guanshen Brian Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology for Animals, Stafford, Queensland, Australia. Hauptthemen laut MEDLINE: Dog Diseases, Lomustine, Pyrimidines, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Canine epitheliotropic T‐cell lymphoma (CETL) is an aggressive and generally incurable disease in dogs. CCNU (lomustine) is commonly used for management, even though it carries a significant risk of adverse effects. Several reports describe oclacitinib producing clinical improvement in affected dogs, yet comparative data between the two treatments are lacking.

Objective

To compare the clinical outcomes in dogs with CETL treated with oclacitinib or CCNU, focussing on tumour reduction (response), survival time and time‐to‐relapse. Materials and Methods This retrospective review (2008–2024) included 23 client‐owned dogs with confirmed CETL treated with either CCNU ( n = 11) or oclacitinib ( n = 12). Outcomes included response (reduction in measurable tumour burden), survival (time from histopathological diagnosis to death) and time‐to‐relapse (for dogs with complete or good responses). Clinical presentation and adverse effects also were recorded. Additionally, sex, age and weight were compared between treatment groups to investigate potential confounding factors.

Results

No statistically significant differences were identified between oclacitinib and CCNU for response, survival or time‐to‐relapse ( p > 0.05 for all). Kaplan–Meier survival analysis showed no significant difference in overall survival (log‐rank test, p = 0.20). Oclacitinib was associated with fewer adverse effects and reduced monitoring intensity. Conclusions and Clinical Relevance These findings suggest oclacitinib may offer outcomes comparable to CCNU for CETL, with fewer adverse effects and less intensive monitoring. The small, retrospective sample limits firm conclusions, yet these results indicate that oclacitinib could be a reasonable, possibly safer palliative option warranting further prospective study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dog DiseasesLomustinePyrimidinesSulfonamidesAntineoplastic AgentsLymphoma, T-CellSkin NeoplasmsAnimalsDogsRetrospective StudiesFemaleMaleNeoplasm Recurrence, LocalTreatment Outcome

Stichwörter der Autor:innen

CCNUETCLcanine cutaneous lymphomaepitheliotropic T‐cell lymphomalomustineoclacitinibtumour burden

Substanzen

LomustinePyrimidinesSulfonamidesoclacitinibAntineoplastic Agents

Autor:innen und Institutionen

  • Dermatology for Animals, Stafford, Queensland, Australia.
  • Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, Adelaide University, Roseworthy, South Australia, Australia.
  • Genomics Research Platform, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria, Australia.
  • Animal Dermatology Specialist, Carrara, Queensland, Australia.
  • School of Veterinary Science, The University of Queensland, Gatton, Queensland, Australia.

ORCID-Profile: Guanshen Brian Shen, Manijeh Mohammadi Dehcheshmeh, Esmaeil Ebrahimie, Evie Knight, Darren J Trott

Zitieren

APA

Shen, G. B., Dehcheshmeh, M. M., Ebrahimie, E., Knight, E., Trott, D. J., & Shipstone, M. (2026). A Retrospective Comparison of Survival, Tumour Reduction and Relapse Outcomes Following Oclacitinib and CCNU Treatment in Dogs With Canine Epitheliotropic T‐Cell Lymphoma. Veterinary Dermatology, 37(6), 1012-1019. https://doi.org/10.1111/vde.70115

Vancouver

Shen GB, Dehcheshmeh MM, Ebrahimie E, Knight E, Trott DJ, Shipstone M. A Retrospective Comparison of Survival, Tumour Reduction and Relapse Outcomes Following Oclacitinib and CCNU Treatment in Dogs With Canine Epitheliotropic T‐Cell Lymphoma. Veterinary Dermatology. 2026;37(6):1012-1019. doi:10.1111/vde.70115

BibTeX
@article{Shen2026,
  author = {Shen, Guanshen Brian and Dehcheshmeh, Manijeh Mohammadi and Ebrahimie, Esmaeil and Knight, Evie and Trott, Darren J and Shipstone, Michael},
  title = {A Retrospective Comparison of Survival, Tumour Reduction and Relapse Outcomes Following Oclacitinib and CCNU Treatment in Dogs With Canine Epitheliotropic T‐Cell Lymphoma},
  journal = {Veterinary Dermatology},
  year = {2026},
  volume = {37},
  number = {6},
  pages = {1012--1019},
  doi = {10.1111/vde.70115}
}
Kostenlos starten →